ライフサイエンスコーパス: virus disease

1 EBOV-GP vaccine in persons at risk for Ebola virus disease.

2 (TEG) in the management of 2 cases of Ebola virus disease.

3 elae seen in West African survivors of Ebola virus disease.

4 safely provide care for patients with Ebola virus disease.

5 ae persist for more than 2 years after Ebola virus disease.

6 de insight into the pathophysiology of Ebola virus disease.

7 with increased likelihood of confirmed Ebola virus disease.

8 ly used hollow-bore needles, developed Ebola virus disease.

9 and virological follow-up of a case of Ebola virus disease.

10 ort, and investigational therapies for Ebola virus disease.

11 d a wide range of diagnoses other than Ebola virus disease.

12 clinical characteristic for confirmed Ebola virus disease.

13 of these health-care workers developed Ebola virus disease.

14 ied this additional indirect burden of Ebola virus disease.

15 AKI has been observed in cases of Ebola virus disease.

16 e the incubation and latent periods of Ebola virus disease.

17 tic testing of patients with suspected Ebola virus disease.

18 model for severe human respiratory syncytial virus disease.

19 l practice guidelines for acute RRT in Ebola virus disease.

20 required for the care of patients with Ebola virus disease.

21 preventive vaccines to protect against Zika virus disease.

22 aling responses in the pathogenesis of Ebola virus disease.

23 ulate the inflammatory response during Ebola virus disease.

24 odies meeting the case definitions for Ebola virus disease.

25 bola virus disease, Lassa fever, and Marburg virus disease.

26 interferons (IFNs) in animal models of Ebola virus disease.

27 the prevention of laboratory confirmed Ebola virus disease.

28 the confirmation of the first case of Ebola virus disease.

29 clinical development for treatment of Ebola virus disease.

30 stexposure prophylaxis; none developed Ebola virus disease.

31 ases, such as Zika virus infection and Ebola virus disease.

32 and younger with laboratory-confirmed Ebola virus disease admitted to EMCs between June and December

33 t focus has been on the recognition of Ebola virus disease among travelers from West Africa, cases of

34 manifestations and adverse outcomes of Zika virus disease among travelers infected in the Americas a

35 manifestations and adverse outcomes of Zika virus disease among travelers infected in the Americas a

36 ions to fully understand the course of Ebola virus disease and adaptation of the virus.

37 or use of post-exposure prophylaxis in Ebola virus disease and identify the priorities for future pre

38 Because of the overlap of symptoms of Ebola virus disease and malaria, the care delivery of malaria

39 98) and age-matched patients with acute Zika virus disease and no neurological symptoms (control grou

40 o decrease the risk of transmission of Ebola virus disease and report pilot data demonstrating no det

41 the four prefectures most affected by Ebola virus disease and selected four randomly from prefecture

42 cination platform in a rodent model of Ebola virus disease and that GP1 N-glycan loss does not influe

43 e information about the pathogenesis of Zika virus disease and the mechanism by which candidate preve

44 ial resources in biological control of plant virus diseases and sustainable agriculture.

45 (IHNV) as a model to study aquatic enveloped virus diseases and their inhibition.

46 hly efficacious and safe in preventing Ebola virus disease, and is most likely effective at the popul

47 re and symptoms of sexually transmitted Zika virus disease, and results of semen testing for Zika vir

48 Patients with Ebola virus disease are often dehydrated and need adequate vas

49 r experience of treating patients with Ebola virus disease at Emory University in the United States.

50 cohort study, consecutive survivors of Ebola virus disease attending Kerry Town survivor clinic (Free

51 The largest outbreak of Ebola virus disease began in Gueckedou, Guinea, West Africa, i

52 mbination increased the probability of Ebola virus disease by 3.2-fold (95% CI 2.3-4.4), but the sens

53 , most assays used in the detection of Ebola virus disease by more than 44 diagnostic laboratories yi

54 ll 28 patients who tested positive for Ebola virus disease by RT-PCR were also positive by fingerstic

55 Prevention of virus disease by vaccination or antiviral agents is diff

56 Severe respiratory syncytial virus disease can be prevented by passively administered

57 Suspected Ebola virus disease case definitions that rely on history of f

58 clinical characteristics of suspected Ebola virus disease cases admitted to Connaught Hospital's Ebo

59 Discrimination of Ebola virus disease cases from patients without the disease is

60 e subsequently classified as confirmed Ebola virus disease cases or non-cases according to the result

61 oup analysis, 15 (9%) of 161 confirmed Ebola virus disease cases reported neither a history of fever

62 In survivors of Ebola virus disease, clinical sequelae including uveitis, arth

63 Ebola virus disease complicated by multiple organ failure can

64 tion of health consequences related to Ebola virus disease could improve patient care for survivors a

65 pitalization of the first patient with Ebola virus disease diagnosed in the United States on 28 Septe

66 assays and the urgent need for a rapid Ebola virus disease diagnosis precluded development of validat

67 t the sensitivity of this strategy for Ebola virus disease diagnosis was low.

68 Inadequate access to rapid testing for Ebola virus disease during the 2014-to-2016 outbreak led to an

69 arch 2016, the West Africa epidemic of Ebola virus disease (Ebola) had resulted in a total of 28,646

70 In 2014, a major epidemic of human Ebola virus disease emerged in West Africa, where human-to-hum

71 dicator across three time periods: pre-Ebola virus disease epidemic (January, 2013, to February, 2014

72 Case fatality in the west African Ebola virus disease epidemic has been highest in children youn

73 vaccines could help to end the ongoing Ebola virus disease epidemic in parts of west Africa, and miti

74 The Ebola virus disease epidemic in West Africa is the largest on

75 work were delayed for months until the Ebola virus disease epidemic was officially declared an emerge

76 case management in the context of the Ebola-virus-disease epidemic and document the effect of the Eb

77 The ongoing west Africa Ebola-virus-disease epidemic has disrupted the entire health-c

78 pidemic and document the effect of the Ebola-virus-disease epidemic on malaria case management.

79 elivery of malaria care because of the Ebola-virus-disease epidemic threatens malaria control in Guin

80 Nationwide, the Ebola-virus-disease epidemic was estimated to have resulted in

81 to the indirect effects of the current Ebola-virus-disease epidemic.

82 and renal failure may occur in severe Ebola virus disease, especially in patients burdened with high

83 697/1054 children testing negative for Ebola virus disease (EVD) and accompanying caregivers.

84 n the characteristics of patients with Ebola virus disease (EVD) and clinical management of EVD in se

85 lth, trauma, and personal exposures to Ebola virus disease (EVD) and health behaviors in post-conflic

86 rsonnel (HCP) caring for patients with Ebola virus disease (EVD) are at increased risk for infection

87 Animal models recapitulating human Ebola virus disease (EVD) are critical for insights into virus

88 e current West African outbreak of the Ebola virus disease (EVD) began in Guinea in December 2013 and

89 An epidemic of Ebola virus disease (EVD) beginning in 2013 has claimed an est

90 Ebola virus disease (EVD) can be caused by four different filo

91 The case fatality ratio (CFR) of Ebola virus disease (EVD) can vary over time and space for rea

92 2014 and February 2015, the number of Ebola virus disease (EVD) cases reported in Sierra Leone decli

93 From 2014 to May 2015, >26 000 Ebola virus disease (EVD) cases were reported from West Africa

94 ned dramatically, sporadic clusters of Ebola virus disease (EVD) continue well beyond the double incu

95 Thousands of people have survived Ebola virus disease (EVD) during the ongoing outbreak.

96 The 2014-2015 Ebola virus disease (EVD) epidemic and international public he

97 The magnitude of the 2013-2016 Ebola virus disease (EVD) epidemic enabled an unprecedented nu

98 The Ebola virus disease (EVD) epidemic has threatened access to ba

99 In the context of the ongoing Ebola virus disease (EVD) epidemic in Liberia, Drake and colle

100 Throughout the Ebola virus disease (EVD) epidemic in West Africa, field labor

101 To combat the 2014-2015 Ebola virus disease (EVD) epidemic in West Africa, the World H

102 is needed to control the unprecedented Ebola virus disease (EVD) epidemic in west Africa.

103 The 2013-2015 Ebola virus disease (EVD) epidemic is caused by the Makona var

104 The 2013-2016 West African Ebola virus disease (EVD) epidemic is the largest recorded.

105 The 2014-15 Ebola virus disease (EVD) epidemic strained health systems in

106 As of November 2015, the Ebola virus disease (EVD) epidemic that began in West Africa i

107 The west Africa Ebola virus disease (EVD) epidemic was extraordinary in scale.

108 e lacking on pregnancy outcomes during Ebola virus disease (EVD) epidemics.

109 Sierra Leone has the most cases of Ebola virus disease (EVD) ever reported.

110 sticks of patients suspected of having Ebola virus disease (EVD) for field diagnostics during an outb

111 ans to manage a patient with confirmed Ebola virus disease (EVD) for the full duration of illness and

112 m the 2013-16 west African outbreak of Ebola virus disease (EVD) has raised several new issues: long-

113 More than 26,000 cases of Ebola virus disease (EVD) have been reported in western Africa

114 Recent models of Ebola Virus Disease (EVD) have often made assumptions about ho

115 nical and virologic characteristics of Ebola virus disease (EVD) in children have not been thoroughly

116 n (WHO) was notified of an outbreak of Ebola virus disease (EVD) in Guinea.

117 Ebola virus disease (EVD) in health workers (HWs) has been a m

118 y experiencing the largest outbreak of Ebola virus disease (EVD) in history.

119 impairment in a cohort of survivors of Ebola virus disease (EVD) in Monrovia, Liberia.

120 In the wake of the recent outbreak of Ebola virus disease (EVD) in several African countries, the Wo

121 scent plasma (CP) for the treatment of Ebola virus disease (EVD) in the current outbreak, predominant

122 The seventh reported outbreak of Ebola virus disease (EVD) in the equatorial African country of

123 As the outbreak of Ebola virus disease (EVD) in West Africa is now contained, att

124 emen of a large number of survivors of Ebola virus disease (EVD) in Western Africa may contribute to

125 aracterize epidemiological patterns of Ebola virus disease (EVD) infections during the West African 2

126 Ebola virus disease (EVD) is a contagious, severe and often le

127 Ebola virus disease (EVD) is a highly lethal condition for whi

128 Ebola virus disease (EVD) is a serious illness with mortality

129 Ebola virus disease (EVD) is a severe viral illness caused by

130 The pathogenesis of human Ebola virus disease (EVD) is complex.

131 apid, accurate, and early diagnosis of Ebola virus disease (EVD) is critical to public health contain

132 (EBOV), but the role of APCs in human Ebola virus disease (EVD) is not known.

133 The 2014-2015 outbreak of Ebola virus disease (EVD) led to more than 27,000 cases and 11

134 Several patients with Ebola virus disease (EVD) managed in the United States have re

135 Experimental treatments for Ebola virus disease (EVD) might reduce EVD mortality.

136 The current West Africa Ebola virus disease (EVD) outbreak has resulted in multiple in

137 The worst Ebola virus disease (EVD) outbreak in history has resulted in

138 , all known transmission chains of the Ebola virus disease (EVD) outbreak in west Africa had been sto

139 The unprecedented 2014-2015 Ebola virus disease (EVD) outbreak in West Africa has highligh

140 int-of-care instruments in the ongoing Ebola virus disease (EVD) outbreak in West Africa would have d

141 Despite the magnitude of the Ebola virus disease (EVD) outbreak in West Africa, there is st

142 The 2013-present Western African Ebola virus disease (EVD) outbreak is the largest ever recorde

143 The West African Ebola virus disease (EVD) outbreak was the largest EVD outbrea

144 uted to the sizable toll of the recent Ebola virus disease (EVD) outbreak.

145 present, there is a major emphasis on Ebola virus disease (EVD) preparedness training at medical fac

146 The unprecedented 2014 epidemic of Ebola virus disease (EVD) prompted an international response t

147 The pathogenesis of Ebola virus disease (EVD) remains unclear.

148 The 2013-2015 West African epidemic of Ebola virus disease (EVD) reminds us of how little is known ab

149 persistence in asymptomatic humans and Ebola virus disease (EVD) sequelae have emerged as significant

150 We report on an Ebola virus disease (EVD) survivor who showed Ebola virus in s

151 nfectious EBOV in semen specimens of 5 Ebola virus disease (EVD) survivors.

152 The overlap of early Ebola virus disease (EVD) symptoms (eg, fever, headache, abdom

153 unparalleled West African outbreak of Ebola virus disease (EVD) that began in late 2013, the lack of

154 quently become the largest epidemic of Ebola virus disease (EVD) to date.

155 l transmission from a male survivor of Ebola virus disease (EVD) to his female partner (the patient i

156 (EMLab) consortium was deployed to the Ebola virus disease (EVD) treatment unit in Gueckedou, Guinea,

157 ty and efficacy of vaccines to prevent Ebola virus disease (EVD) were unknown when the incidence of E

158 ious it could explain re-emergences of Ebola virus disease (EVD) without known contact.

159 Ebola virus disease (EVD), a severe viral hemorrhagic fever sy

160 as been developed for the treatment of Ebola virus disease (EVD), but its efficacy and safety in huma

161 Among the survivors of Ebola virus disease (EVD), complications that include uveitis

162 een deforestation and the emergence of Ebola virus disease (EVD), however, is still missing.

163 The largest-ever outbreak of Ebola virus disease (EVD), ongoing in West Africa since late 2

164 than 30 000 individuals have acquired Ebola virus disease (EVD), the medical and scientific communit

165 f virus replication, viremia and fatal Ebola virus disease (EVD).

166 , that is produced in abundance during Ebola virus disease (EVD).

167 s of clinical sequelae in survivors of Ebola virus disease (EVD).

168 a promising immune-based treatment for Ebola virus disease (EVD).

169 sponse workers with suspected or known Ebola virus disease (EVD).

170 collected from persons diagnosed with Ebola virus disease (EVD).

171 semen of men after their recovery from Ebola virus disease (EVD).

172 ction of nonhuman primates from deadly Ebola virus disease, even when treatment was begun as late as

173 history of fever and risk factors for Ebola virus disease exposure do not have sufficient sensitivit

174 history of fever nor a risk factor for Ebola virus disease exposure.

175 e selection of patients with suspected Ebola virus disease for admission by identifying presenting cl

176 nd therapy development, and control of Ebola virus disease for noninfectious disease physicians.

177 ccination group there were 16 cases of Ebola virus disease from seven clusters, showing a vaccine eff

178 The epidemic of Ebola virus disease has spread at an alarming rate despite con

179 international responders, few cases of Ebola virus disease have been diagnosed in this group.

180 e limited data available for long-term Ebola virus disease health outcomes suggest that sequelae pers

181 We regarded samples to be positive for Ebola virus disease if the cycle threshold was 40 or lower.

182 ytokine response that is a hallmark of Ebola virus disease.IMPORTANCE Understanding how the host resp

183 vaccination trial, suspected cases of Ebola virus disease in Basse-Guinee (Guinea, west Africa) were

184 the effect of rVSV-ZEBOV in preventing Ebola virus disease in contacts and contacts of contacts of re

185 ary analysis compared the incidence of Ebola virus disease in eligible and vaccinated individuals ass

186 protocol and compared the incidence of Ebola virus disease in eligible and vaccinated individuals in

187 Ebola virus disease in humans is highly lethal, with case fata

188 pecies in the genus are known to cause Ebola Virus Disease in humans.

189 aches taken for treating patients with Ebola virus disease in low- and high-resource settings.

190 In 1976, the first cases of Ebola virus disease in northern Democratic Republic of the Con

191 The 2014 epidemic of Ebola virus disease in parts of west Africa defines an unprece

192 describe clinicopathologic features of Ebola virus disease in pregnancy.

193 vided no benefit for the prevention of Ebola virus disease in rhesus macaques with regards to reducti

194 provision of care of two patients with Ebola virus disease in the biocontainment unit at the Universi

195 alence and severity of respiratory syncytial virus disease in the first few weeks of life, whereas ma

196 ical manifestations and epidemiology of Zika virus disease in travelers exposed in the Americas.

197 ical manifestations and epidemiology of Zika virus disease in travelers exposed in the Americas.

198 The massive outbreak of Ebola virus disease in west Africa between 2013 and 2016 resul

199 The recent epidemic of Ebola virus disease in West Africa resulted in an unprecedente

200 The 2013-2016 epidemic of Ebola virus disease in West Africa was of unprecedented magnit

201 During the latest outbreak of Ebola virus disease in West Africa, monoclonal antibody therap

202 CT]) for all contacts of patients with Ebola virus disease (in terms of administration and averted ET

203 We projected district-level Ebola virus disease incidence for the next 6 months, using a s

204 For an SWCT, regional variation in Ebola virus disease incidence trends produced increased false-

205 and 26% for an SWCT, depending on the Ebola virus disease incidence within the trial population.

206 the provision of care to patients with Ebola virus disease, including absence of pre-existing isolati

207 ed for the prevention and treatment of Ebola virus disease, including following a potentially high-ri

208 nonhuman primates against all signs of Ebola virus disease, including viremia.

209 and June 16, 2015, of 151 survivors of Ebola virus disease invited to participate, 112 (74%) provided

210 Ebola virus disease is a serious illness of humans and nonhuma

211 Ebola virus disease is associated with a high prevalence of ha

212 Providing RRT in Ebola virus disease is complex and requires meticulous attenti

213 n Sierra Leone, where the incidence of Ebola virus disease is spatiotemporally heterogeneous, and is

214 In its largest outbreak, Ebola virus disease is spreading through Guinea, Liberia, Sier

215 ica, Crimean-Congo haemorrhagic fever, Ebola virus disease, Lassa fever, and Marburg virus disease.

216 In the severe form, patients with Ebola virus disease may require life-sustaining therapy, inclu

217 n medically evacuated for treatment of Ebola virus disease, more commonly they were evacuated after p

218 d was confirmed to be an outbreak of Marburg virus disease (MVD).

219 l 117 clusters showed that no cases of Ebola virus disease occurred 10 days or more after randomisati

220 No cases of Ebola virus disease occurred 10 days or more after randomisati

221 No secondary cases of Ebola virus disease occurred among the vaccinees.

222 An epidemic of Ebola virus disease of unprecedented scale has been ongoing fo

223 Virus diseases of perennial trees and vines have charact

224 n Freetown were screened for suspected Ebola virus disease on arrival and, if necessary, were admitte

225 n could largely mitigate the effect of Ebola virus disease on malaria.

226 sought to quantify the consequences of Ebola virus disease on maternal and child health services in t

227 tly infected individuals with no evidence of virus disease or dissemination.

228 tors significantly declined during the Ebola virus disease outbreak in 2014.

229 During the ongoing Ebola virus disease outbreak in parts of Western Africa, most

230 After the detection of an Ebola virus disease outbreak in west Africa in 2014, one of th

231 The Ebola virus disease outbreak in west Africa is pivotal for the

232 The 2013-16 Ebola virus disease outbreak in west Africa was associated wit

233 The Ebola virus disease outbreak in West Africa was unprecedented

234 The magnitude of the 2013-2016 Ebola virus disease outbreak in West Africa was unprecedented,

235 ich are being assessed during the 2014 Ebola virus disease outbreak in west Africa.

236 The largest ever Ebola virus disease outbreak is ravaging West Africa.

237 The size of the west African Ebola virus disease outbreak led to the urgent establishment o

238 at a human survivor of the 1995 Kikwit Ebola virus disease outbreak maintained circulating antibodies

239 In the post-Ebola virus disease outbreak period, vaccination coverage for

240 Compared with pre-Ebola virus disease outbreak trends, significant decreases occ

241 ulation level when delivered during an Ebola virus disease outbreak via a ring vaccination strategy.

242 In the months before the Ebola virus disease outbreak, all three maternal indicators sh

243 ublic health officials when addressing Ebola virus disease outbreaks in countries and seasons where m

244 ly implemented at scale in response to Ebola virus disease outbreaks in rural settings.

245 In 49 patients with known Ebola virus disease outcomes during the ongoing outbreak in Si

246 escription of the clinical features of Ebola virus disease over the duration of illness in children a

247 Our knowledge relating to the virus, disease pathogenesis, risk factors, dynamics of t

248 critical role for the delta peptide in Ebola virus disease pathology and as a possible target for nov

249 t may be a novel, targetable aspect of Ebola virus disease pathology.IMPORTANCE During the unparallel

250 pment (PPE) during care activities for Ebola virus disease patients has not yet been characterized.

251 The 2014 west African epidemic of Ebola virus disease posed a major threat to the health systems

252 Ebola virus disease poses a global health threat.

253 es from 106 individuals with suspected Ebola virus disease presenting at two clinical centres in Sier

254 ative agent of the largest outbreak of Ebola Virus Disease recorded.

255 ted positive 12 months or longer after Ebola virus disease recovery.

256 Clinical management of Ebola virus disease remains challenging.

257 Ebola virus disease represents an illness ready for a paradigm

258 fe and effective care of patients with Ebola virus disease requires significant communication and pla

259 At present, diagnosis of Ebola virus disease requires transport of venepuncture blood t

260 form future treatment of patients with Ebola virus disease requiring critical care treatment.

261 r cases in the community, impeding the Ebola-virus-disease response.

262 dengue, chikungunya, yellow fever, and Zika virus disease) resulting from the triad of the modern wo

263 e, or clinically suspected diagnosis of Zika virus disease seen between January 2013 and 29 February

264 e, or clinically suspected diagnosis of Zika virus disease seen between January 2013 and 29 February

265 Influenza virus disease severity is influenced by viral virulence

266 treatment to contacts of patients with Ebola virus disease should be considered by public health offi

267 has experienced the most outbreaks of Ebola virus disease since the virus' discovery in 1976.

268 for management of whiteflies to reduce plant virus disease spread.

269 la virus has been detected in semen of Ebola virus disease survivors after recovery.

270 As of May 6, 2016, 466 Ebola virus disease survivors had enrolled in the programme; r

271 Health Screening Program (MHSP) offers Ebola virus disease survivors semen testing for Ebola virus.

272 's Health Screening Program helps male Ebola virus disease survivors understand their individual risk

273 The West African outbreak of Ebola virus disease that peaked in 2014 has caused more than 1

274 n the concern about potentially lethal Ebola virus disease, the patient was offered, and provided his

275 y and clinical data from patients with Ebola virus disease to better inform clinical management algor

276 tment to all contacts of patients with Ebola virus disease, to prevent the onset of febrile malaria a

277 quent renal recovery in a patient with Ebola virus disease treated at Emory University Hospital, in A

278 64%) of these patients, a diagnosis of Ebola virus disease was confirmed.

279 n of ACTs to contacts of patients with Ebola virus disease was cost saving for contacts of all ages i

280 , the characteristic histopathology of Ebola virus disease was not observed, and this absence of seve

281 In March, 2016, a flare-up of Ebola virus disease was reported in Guinea, and in response ri

282 After confirmation of a case of Ebola virus disease, we definitively enumerated on a list a ri

283 m optimal care in a future outbreak of Ebola virus disease, we employed the Grading of Recommendation

284 c 8, 2014, 850 patients with suspected Ebola virus disease were admitted to the holding unit, of whom

285 gust 2016, 256343 specimens tested for Ebola virus disease were captured in the database.

286 No new cases of Ebola virus disease were diagnosed in vaccinees from the immed

287 Starting in May 2015, 93 cases of Zika virus disease were reported.

288 ults: Starting in May 2015, 93 cases of Zika virus disease were reported.

289 rVSVDeltaG-ZEBOV-GP vaccine prevented Ebola virus disease when used at 2 x 107 plaque-forming units

290 Patients recovering from Ebola virus disease who do not meet the case definition for ac

291 ents, alive on arrival, with confirmed Ebola virus disease who were admitted to the Kerry Town Ebola

292 s report describes three patients with Ebola virus disease who were treated in the United States and

293 ributed to our better understanding of Ebola virus disease with a paper underlying the crucial role o

294 atient who had been treated for severe Ebola virus disease with high viral load (peak cycle threshold

295 ome was a laboratory confirmed case of Ebola virus disease with onset 10 days or more from randomisat

296 imary outcome was laboratory-confirmed Ebola virus disease with onset of symptoms at least 10 days af

297 cination group, there were no cases of Ebola virus disease with symptom onset at least 10 days after

298 offers substantial protection against Ebola virus disease, with no cases among vaccinated individual

299 offers substantial protection against Ebola virus disease, with no cases among vaccinated individual

300 olombia began official surveillance for Zika virus disease (ZVD) in August 2015.